OBJECTIVES: A number of herbal dietary antioxidant supplements containing Indole-3 Carbinol (I3C) and Resveratrol (RE) have been established as anti-proliferative agents in cancer. These compounds have both similar as well as unique molecular targeting profiles. The purpose of this study is to analyze their mechanism of action when used individually and in combination in ovarian cancer. METHODS: SK-OV-3 ovarian cancer cells were treated with various doses of I3C, RE or I3C+RE. AlamarBlue dye assay was used to examine cell growth and proliferation. Cell cycle and apoptosis were analyzed by flow cytometry. Western blot was performed to determine the expression of the genes associated with cell cycle and apoptosis. CA-125, a functional marker of ovarian cancer, and nitric oxide, were analyzed by ELISA. RESULTS: I3C or RE inhibited cell proliferation, and caused cell contraction and apoptosis. Analysis of apoptosis-associated genes revealed an inhibition of Retinoblastoma protein (Rb) and Survivin (SVV) gene expression. This was accompanied by elevation of p21, a tumor suppressor. Cell cycle was inhibited at both G1 and G2/M by individual treatments, and accentuated by a combination. AlamarBlue assay revealed a clear synergistic action of I3C+RE. CA125 was inhibited by either I3C or RE treatments. In contrast, basal nitric oxide production was inhibited by I3C and I3C+RE but not RE alone. CONCLUSIONS: This is the first evidence demonstrating the effects of I3C on ovarian cancer cells and its synergism with RE. Based on this model, our data indicate that combinations of compounds with different targeting properties will be more effective in chemoprevention and/or chemotherapy of ovarian and possibly other cancers.
OBJECTIVES: A number of herbal dietary antioxidant supplements containing Indole-3 Carbinol (I3C) and Resveratrol (RE) have been established as anti-proliferative agents in cancer. These compounds have both similar as well as unique molecular targeting profiles. The purpose of this study is to analyze their mechanism of action when used individually and in combination in ovarian cancer. METHODS:SK-OV-3 ovarian cancer cells were treated with various doses of I3C, RE or I3C+RE. AlamarBlue dye assay was used to examine cell growth and proliferation. Cell cycle and apoptosis were analyzed by flow cytometry. Western blot was performed to determine the expression of the genes associated with cell cycle and apoptosis. CA-125, a functional marker of ovarian cancer, and nitric oxide, were analyzed by ELISA. RESULTS:I3C or RE inhibited cell proliferation, and caused cell contraction and apoptosis. Analysis of apoptosis-associated genes revealed an inhibition of Retinoblastoma protein (Rb) and Survivin (SVV) gene expression. This was accompanied by elevation of p21, a tumor suppressor. Cell cycle was inhibited at both G1 and G2/M by individual treatments, and accentuated by a combination. AlamarBlue assay revealed a clear synergistic action of I3C+RE. CA125 was inhibited by either I3C or RE treatments. In contrast, basal nitric oxide production was inhibited by I3C and I3C+RE but not RE alone. CONCLUSIONS: This is the first evidence demonstrating the effects of I3C on ovarian cancer cells and its synergism with RE. Based on this model, our data indicate that combinations of compounds with different targeting properties will be more effective in chemoprevention and/or chemotherapy of ovarian and possibly other cancers.
Authors: Dixan A Benitez; Eulalia Pozo-Guisado; Alberto Alvarez-Barrientos; Pedro M Fernandez-Salguero; Enrique A Castellón Journal: J Androl Date: 2006-10-18
Authors: Anthony W Opipari; Lijun Tan; Anthony E Boitano; Dorothy R Sorenson; Anjili Aurora; J Rebecca Liu Journal: Cancer Res Date: 2004-01-15 Impact factor: 12.701
Authors: Sang Hwa Yang; Jong Sik Kim; Tae Jeong Oh; Myung Soon Kim; Sun Woo Lee; Suk Kyung Woo; Hyun Sill Cho; Yung Hyun Choi; Young Ho Kim; Sun Young Rha; Hyun Cheol Chung; Sung Whan An Journal: Int J Oncol Date: 2003-04 Impact factor: 5.650
Authors: Scott N Pinchot; Renata Jaskula-Sztul; Li Ning; Noel R Peters; Mackenzie R Cook; Muthusamy Kunnimalaiyaan; Herbert Chen Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Karuppaiyah Selvendiran; Liyue Tong; Anna Bratasz; M Lakshmi Kuppusamy; Shabnam Ahmed; Yazhini Ravi; Nancy J Trigg; Brian K Rivera; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy Journal: Mol Cancer Ther Date: 2010-05-04 Impact factor: 6.261
Authors: José Díaz-Chávez; Miguel A Fonseca-Sánchez; Elena Arechaga-Ocampo; Ali Flores-Pérez; Yadira Palacios-Rodríguez; Guadalupe Domínguez-Gómez; Laurence A Marchat; Lizeth Fuentes-Mera; Guillermo Mendoza-Hernández; Patricio Gariglio; César López-Camarillo Journal: PLoS One Date: 2013-05-27 Impact factor: 3.240
Authors: B Taylor-Harding; H Agadjanian; H Nassanian; S Kwon; X Guo; C Miller; B Y Karlan; S Orsulic; C S Walsh Journal: Br J Cancer Date: 2011-12-13 Impact factor: 7.640
Authors: Mohamed F Ismail; Doaa A Ali; Augusta Fernando; Mohamed E Abdraboh; Rajiv L Gaur; Wael M Ibrahim; Madhwa H G Raj; Allal Ouhtit Journal: Int J Biol Sci Date: 2009-06-02 Impact factor: 6.580
Authors: Justyna Mikuła-Pietrasik; Patrycja Sosińska; Marek Murias; Marcin Wierzchowski; Marta Brewińska-Olchowik; Katarzyna Piwocka; Dariusz Szpurek; Krzysztof Książek Journal: Oxid Med Cell Longev Date: 2015-07-01 Impact factor: 6.543